New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
07:15 EDTATHX, NBS, PSTI, CUR, OSIR, BCLIRRY Publications to host a summit
8th Annual New York Stem Cell Summit '13 is being held in New York on February 19.
News For OSIR;PSTI;ATHX;CUR;NBS;BCLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
08:02 EDTOSIROsiris reports Q4 EPS 3c, two estimates 5c
Reports Q4 revenue $19.3M, two estimates $18.9M.
March 3, 2015
05:30 EDTPSTIPluristem announce data showing PLX-R18 cells improve bone marrow transplant
Subscribe for More Information
March 2, 2015
16:09 EDTNBSNeoStem provides 2015 outlook
In 2015, NeoStem's management expects significant additional achievements. The Company's milestones and goals for the year include: Randomization of the first patient for the Intus Phase 3 trial for NBS20 in the second quarter of 2015; Release of one-year data from PreSERVE AMI Phase 2 trial for NBS10 on March 15, 2015 at the Annual Scientific Sessions of the American College of Cardiology; Finalization of decision on next development steps for NBS10 based on PreSERVE primary analysis results in the second half of 2015; Initiation of a Phase 2 study for which NeoStem has received FDA agreement on the protocol to evaluate in adolescents the use of NBS03D, a Treg-based therapeutic being developed to treat type 1 diabetes, in late 2015 or 2016 depending on resource availability; Further exploration of means by which the Company can take advantage of new regulations in Japan that permit conditional approval for regenerative medicine products that show sufficient safety evidence and signals of efficacy; Continued growth of the Company's client services business; Advancement of initiatives to lower costs and improve efficiency of manufacturing in anticipation of production for NeoStem's own products and those of its clients.
09:22 EDTATHXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Amira Nature Foods (ANFI), up 8.6%... Stratasys (SSYS), up 3.6%... Magnum Hunter (MHR), up 3%. ALSO HIGHER: Mavenir Systems (MVNR), up 19.1% after Mitel (MITL) agrees to acquire Mavenir Systems for $560M... Athersys (ATHX), up 19.7% following license agreement and collaboration with Chugai... OHR Pharmaceutical (OHRP), up 11.4% following additional positive data from OHR-102 IMPACT study... NXP Semiconductors (NXPI), up 14% following merger agreement with Freescale Semiconductor (FSL). Freescale Semiconductor is up 9.1%... Mast Therapeutics (MSTX), up 7.7% following positive results from Vepoloxamer study. DOWN AFTER EARNINGS: JinkoSolar (JKS), down 4.7%... Scorpio Tankers (STNG), down 4.5%. ALSO LOWER: Lumber Liquidators (LL), down 24.2% following CBS' 60 Minutes says that the company is linked to health and safety violations... Aruba Networks (ARUN), down 1.7% after HP (HPQ) confirms deal to acquire Aruba Networks for $24.67... Pacira Pharmaceuticals (PCRX), down 14.4% after receiving complete response letter from FDA for sNDA in use of Exparel... 500.com (WBAI), down 14.4% after announcing that temporary suspension will adversely impact financial results.
05:58 EDTATHXAthersys and Chugai enter license agreement and collaboration
Subscribe for More Information
February 24, 2015
07:33 EDTATHXMaxim to hold a discussion
Subscribe for More Information
February 19, 2015
12:50 EDTPSTIPluristem says NIH study of PLX-R18 statistically significant
Pluristem Therapeutics announced the results of a recently completed trial conducted by the U.S. National Institutes of Health to evaluate PLX-R18 cells to treat bone marrow damaged by exposure to high levels of radiation, such as can occur after a nuclear disaster. Injection of PLX-R18 cells into muscle, as compared to a placebo, resulted in a statistically significant improvement in the recovery of white blood cell, red blood cell, and platelet levels in animals exposed to high levels of radiation, the company said. It added, "The data also suggested that the treatment may potentially be able to shorten time to recovery."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use